Predictors of major bleeding in patients with atrial fibrillation treated with rivaroxaban in XANTUS: findings from a real-world prospective study

被引：0
|
作者：
Kirchhof, P. [1 ,2 ]
Haas, S. [3 ]
Amarenco, P. [4 ,5 ]
Hess, S. [6 ]
Kuhls, S. [7 ]
Van Eickels, M. [8 ]
Turpie, A. G. G. [9 ]
Camm, A. J. [10 ]
机构：
[1] Univ Birmingham, Inst Cardiovasc Sci, UHB Hosp NHS Trust, Birmingham, W Midlands, England
[2] Univ Birmingham, Inst Cardiovasc Sci, Sandwell & West Birmingham Hosp NHS Trust, Birmingham, W Midlands, England
[3] Vasc Ctr, Munich, Germany
[4] Paris Diderot Sorbonne Univ, Dept Neurol, Paris, France
[5] Paris Diderot Sorbonne Univ, Stroke Ctr, Paris, France
[6] Bayer Healthcare Co Ltd, Med Affairs, Beijing, Peoples R China
[7] Bayer Pharma AG, Global Integrated Anal, Wuppertal, Germany
[8] Bayer Pharma AG, Med Affairs, Berlin, Germany
[9] McMaster Univ, Dept Med, Hamilton, ON, Canada
[10] St Georges Univ London, Cardiovasc & Cell Sci Res Inst, London, England
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P2606
引用
收藏
页码：512 / 513
页数：2
相关论文
共 50 条
  • [31] Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation
    Takanari Kitazono
    Takanori Ikeda
    Satoshi Ogawa
    Jyoji Nakagawara
    Kazuo Minematsu
    Susumu Miyamoto
    Yuji Murakawa
    Mary Cavaliere
    Yasuhiro Hayashi
    Yoko Kidani
    Yutaka Okayama
    Toshiyuki Sunaya
    Shoichiro Sato
    Satoshi Yamanaka
    Heart and Vessels, 2020, 35 : 399 - 408
  • [32] Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation
    Kitazono, Takanari
    Ikeda, Takanori
    Ogawa, Satoshi
    Nakagawara, Jyoji
    Minematsu, Kazuo
    Miyamoto, Susumu
    Murakawa, Yuji
    Cavaliere, Mary
    Hayashi, Yasuhiro
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    Yamanaka, Satoshi
    HEART AND VESSELS, 2020, 35 (03) : 399 - 408
  • [33] XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
    Camm, A. John
    Amarenco, Pierre
    Haas, Sylvia
    Hess, Susanne
    Kirchhof, Paulus
    Van Eickels, Martin
    Turpie, Alexander G. G.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 425 - 434
  • [34] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Tepper, Ping G.
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    Kamble, Shital
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    PLOS ONE, 2018, 13 (11):
  • [35] REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN
    Amin, Alpesh
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Mardekian, Jack
    Mendoza, Mario
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 668 - 668
  • [36] Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan
    Miyamoto, Susumu
    Ikeda, Takanori
    Ogawa, Satoshi
    Kitazono, Takanari
    Nakagawara, Jyoji
    Minematsu, Kazuo
    Murakawa, Yuji
    Iwashiro, Sanghun
    Takeichi, Makiko
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    Yamanaka, Satoshi
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2020, 29 (04):
  • [37] Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function
    Nakagawara, Jyoji
    Ikeda, Takanori
    Ogawa, Satoshi
    Kitazono, Takanari
    Minematsu, Kazuo
    Miyamoto, Susumu
    Murakawa, Yuji
    Takeichi, Makiko
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    Yamanaka, Satoshi
    JOURNAL OF CARDIOLOGY, 2019, 74 (5-6) : 501 - 506
  • [38] Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies
    Deitelzweig, S.
    Farmer, C.
    Luo, X.
    Vo, L.
    Li, X.
    Hamilton, M.
    Horblyuk, R.
    Ashaye, A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (09) : 1583 - 1594
  • [39] Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin
    Albabtain, Monirah Abdulrahman
    Alanazi, Zaid Dakheel
    Al-Mutairi, Nawaf Hamoud
    Alyafi, Ola
    Albanyan, Raneem
    Arafat, Amr A.
    HEART VIEWS, 2023, 24 (03): : 136 - 140
  • [40] A Real-World Comparison of Apixaban and Rivaroxaban in Obese and Morbidly Obese Patients With Nonvalvular Atrial Fibrillation
    Burnham, Kevin T.
    Yang, Tianrui
    Wooster, Jessica
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (04) : 916 - 921
12345